Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer

(2020) Adrienne G. Waks et al.   ANNALS OF ONCOLOGY

53BP1: a DSB escort

(2020) Zachary Mirman et al.   GENES & DEVELOPMENT

PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications

(2020) Heng Zhu et al.   Molecular Cancer

The antitumorigenic roles of BRCA1–BARD1 in DNA repair and replication

(2020) Madalena Tarsounas et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Synergistic lethality between PARP-trapping and alantolactone-induced oxidative DNA damage in homologous recombination-proficient cancer cells

(2020) Hongge Wang et al.   ONCOGENE

PALB2 chromatin recruitment restores homologous recombination in BRCA1-deficient cells depleted of 53BP1

(2020) Rimma Belotserkovskaya et al.   Nature Communications

Role of Akt Activation in PARP Inhibitor Resistance in Cancer

(2020) Ferenc Gallyas Jr et al.   Cancers

Inactivation of the Prolyl Isomerase Pin1 Sensitizes BRCA1-Proficient Breast Cancer to PARP Inhibition

(2020) Man-Li Luo et al.   CANCER RESEARCH

Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells

(2020) Rebecca L. Lloyd et al.   ONCOGENE

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer

(2020) Neha Chopra et al.   Nature Communications

XPF-ERCC1 protects liver, kidney and blood homeostasis outside the canonical excision repair pathways

(2020) Lee Mulderrig et al.   PLoS Genetics

A Novel Mechanism to Induce BRCAness in Cancer Cells

(2020) Changmeng Cai   CANCER RESEARCH

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models

(2020) Hyoung Kim et al.   Nature Communications

Visualization of DNA Repair Proteins Interaction by Immunofluorescence

(2020) Bárbara de la Peña Avalos et al.   Jove-Journal of Visualized Experiments

Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells

(2020) Miriam K. Gomez et al.   Cancers

Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer

(2019) Chee Khoon Lee et al.   BRITISH JOURNAL OF CANCER

ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks

(2019) Gabriel Balmus et al.   Nature Communications

Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy

(2019) Yong Fang et al.   CANCER CELL

PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside

(2019) Ali S. Alzahrani   SEMINARS IN CANCER BIOLOGY

PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells

(2019) Sylvie M. Noordermeer et al.   TRENDS IN CELL BIOLOGY

In vitro role of Rad54 in Rad51-ssDNA filament-dependent homology search and synaptic complexes formation

(2019) Eliana Moreira Tavares et al.   Nature Communications

RAD51 is a potential marker for prognosis and regulates cell proliferation in pancreatic cancer

(2019) Xiaomeng Zhang et al.   Cancer Cell International

Selective small molecule PARG inhibitor causes replication fork stalling and cancer cell death

(2019) Jerry H. Houl et al.   Nature Communications

BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency

(2018) Chaoyang Sun et al.   CANCER CELL

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality

(2018) Ewa Gogola et al.   CANCER CELL

Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer

(2018) Yi-Mi Wu et al.   CELL

Ku DNA End-Binding Activity Promotes Repair Fidelity and Influences End-Processing During Nonhomologous End-Joining inSaccharomyces cerevisiae

(2018) Charlene H. Emerson et al.   GENETICS

The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer

(2018) Andrew J. Wilson et al.   GYNECOLOGIC ONCOLOGY

SLFN11 Blocks Stressed Replication Forks Independently of ATR

(2018) Junko Murai et al.   MOLECULAR CELL

Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance

(2018) Stephen J. Pettitt et al.   Nature Communications

Analysis of PARP inhibitor toxicity by multidimensional fluorescence microscopy reveals mechanisms of sensitivity and resistance

(2018) Jone Michelena et al.   Nature Communications

Ku DNA End-Binding Activity Promotes Repair Fidelity and Influences End-Processing During Nonhomologous End-Joining inSaccharomyces cerevisiae

(2018) Charlene H. Emerson et al.   GENETICS

High speed of fork progression induces DNA replication stress and genomic instability

(2018) Apolinar Maya-Mendoza et al.   NATURE

The shieldin complex mediates 53BP1-dependent DNA repair

(2018) Sylvie M. Noordermeer et al.   NATURE

The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers

(2018) Antonio Marzio et al.   MOLECULAR CELL

DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells

(2018) Yizhou Joseph He et al.   NATURE

The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity

(2018) Jordan R. Becker et al.   Nature Communications

ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells

(2017) Stephanie A. Yazinski et al.   GENES & DEVELOPMENT

Nonhomologous End-Joining with Minimal Sequence Loss Is Promoted by the Mre11-Rad50-Nbs1-Ctp1 Complex inSchizosaccharomyces pombe

(2017) Yanhui Li et al.   GENETICS

Nucleotide excision repair is a potential therapeutic target in multiple myeloma

(2017) R Szalat et al.   LEUKEMIA

Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response–Targeted Therapies in Breast Cancer

(2017) Kalnisha Naidoo et al.   MOLECULAR CANCER THERAPEUTICS

Coupling of Homologous Recombination and the Checkpoint by ATR

(2017) Rémi Buisson et al.   MOLECULAR CELL

DNA Double-Strand Break Resection Occurs during Non-homologous End Joining in G1 but Is Distinct from Resection during Homologous Recombination

(2017) Ronja Biehs et al.   MOLECULAR CELL

Restoration of Replication Fork Stability in BRCA1- and BRCA2-Deficient Cells by Inactivation of SNF2-Family Fork Remodelers

(2017) Angelo Taglialatela et al.   MOLECULAR CELL

ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response

(2017) Andrew N. Blackford et al.   MOLECULAR CELL

EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation

(2017) Beatrice Rondinelli et al.   NATURE CELL BIOLOGY

Tuning BRCA1 and BARD1 activity to investigate RING ubiquitin ligase mechanisms

(2017) Mikaela D. Stewart et al.   PROTEIN SCIENCE

Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

(2017) Olga Kondrashova et al.   Cancer Discovery

The relevance of prelamin A and RAD51 as molecular biomarkers in cervical cancer

(2017) Simona Leonardi et al.   Oncotarget

BRCA1 Directs the Repair Pathway to Homologous Recombination by Promoting 53BP1 Dephosphorylation

(2017) Mayu Isono et al.   Cell Reports

BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer

(2017) Sergey Karakashev et al.   Cell Reports

A PALB2-interacting domain in RNF168 couples homologous recombination to DNA break-induced chromatin ubiquitylation

(2017) Martijn S Luijsterburg et al.   eLife

Nonhomologous End-Joining with Minimal Sequence Loss Is Promoted by the Mre11-Rad50-Nbs1-Ctp1 Complex inSchizosaccharomyces pombe

(2017) Yanhui Li et al.   GENETICS

ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells

(2016) Aparajitha Vaidyanathan et al.   BRITISH JOURNAL OF CANCER

PARG deficiency is neither synthetic lethal with BRCA1 nor PTEN deficiency

(2016) Aurélia Noll et al.   Cancer Cell International

RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer

(2016) Yajing Liu et al.   CLINICAL CANCER RESEARCH

Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline

(2016) Hope S. Rugo et al.   JOURNAL OF CLINICAL ONCOLOGY

Mismatch Repair and Colon Cancer: Mechanisms and Therapies Explored

(2016) Stephen K.H. Li et al.   TRENDS IN MOLECULAR MEDICINE

Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer

(2016) Dong Wang et al.   Oncotarget

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition

(2016) Junko Murai et al.   Oncotarget

Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities

(2016) Kumar Sanjiv et al.   Cell Reports

CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer

(2016) Shawn F. Johnson et al.   Cell Reports

FANCD2 Maintains Fork Stability in BRCA1/2-Deficient Tumors and Promotes Alternative End-Joining DNA Repair

(2016) Zeina Kais et al.   Cell Reports

Rad51 Paralogs Remodel Pre-synaptic Rad51 Filaments to Stimulate Homologous Recombination

(2015) Martin R.G. Taylor et al.   CELL

Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer

(2015) Yung-Jue Bang et al.   JOURNAL OF CLINICAL ONCOLOGY

A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition

(2015) D. A. Alagpulinsa et al.   MOLECULAR CANCER THERAPEUTICS

REV7 counteracts DNA double-strand break resection and affects PARP inhibition

(2015) Guotai Xu et al.   NATURE

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

(2015) Joaquin Mateo et al.   NEW ENGLAND JOURNAL OF MEDICINE

DNA-Pairing and Annealing Processes in Homologous Recombination and Homology-Directed Repair

(2015) Scott W. Morrical   Cold Spring Harbor Perspectives in Biology

Homologous Recombination and Human Health: The Roles of BRCA1, BRCA2, and Associated Proteins

(2015) Rohit Prakash et al.   Cold Spring Harbor Perspectives in Biology

A multi-institutional study of the prevalence of BRCA1 and BRCA2 large genomic rearrangements in familial breast cancer patients

(2014) Moon-Woo Seong et al.   BMC CANCER

Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: A systematic review and meta-analysis

(2014) Esther Molina-Montes et al.   BREAST

Mediators of Homologous DNA Pairing

(2014) A. Zelensky et al.   Cold Spring Harbor Perspectives in Biology

Biallelic Mutations in BRCA1 Cause a New Fanconi Anemia Subtype

(2014) Sarah L. Sawyer et al.   Cancer Discovery

Is Non-Homologous End-Joining Really an Inherently Error-Prone Process?

(2014) Mireille Bétermier et al.   PLoS Genetics

Breast Cancer Following Ovarian Cancer inBRCAMutation Carriers

(2014) Alexandra Gangi et al.   JAMA Surgery

Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines

(2013) Aisling Pierce et al.   CANCER BIOLOGY & THERAPY

Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity

(2013) I. Bajrami et al.   CANCER RESEARCH

Deficiency of terminal ADP-ribose protein glycohydrolase TARG1/C6orf130 in neurodegenerative disease

(2013) Reza Sharifi et al.   EMBO JOURNAL

Causes and consequences of replication stress

(2013) Michelle K. Zeman et al.   NATURE CELL BIOLOGY

The Shu complex interacts with Rad51 through the Rad51 paralogues Rad55–Rad57 to mediate error-free recombination

(2013) Stephen Godin et al.   NUCLEIC ACIDS RESEARCH

53BP1 Regulates DSB Repair Using Rif1 to Control 5' End Resection

(2013) M. Zimmermann et al.   SCIENCE

Targeting Apoptosis Pathways in Cancer with Alantolactone and Isoalantolactone

(2013) Azhar Rasul et al.   TheScientificWorldJOURNAL

53BP1: pro choice in DNA repair

(2013) Michal Zimmermann et al.   TRENDS IN CELL BIOLOGY

Mammalian Transcription-Coupled Excision Repair

(2013) W. Vermeulen et al.   Cold Spring Harbor Perspectives in Biology

Substrate-Selective Repair and Restart of Replication Forks by DNA Translocases

(2013) Rémy Bétous et al.   Cell Reports

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer

(2012) V Abkevich et al.   BRITISH JOURNAL OF CANCER

Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation

(2012) T. Popova et al.   CANCER RESEARCH

Inhibition of poly(ADP-ribose) glycohydrolase (PARG) specifically kills BRCA2-deficient tumor cells

(2012) Catherine Fathers et al.   CELL CYCLE

RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma

(2012) Pierre Tennstedt et al.   INTERNATIONAL JOURNAL OF CANCER

Secondary mutations inBRCA2associated with clinical resistance to a PARP inhibitor

(2012) Louise J Barber et al.   JOURNAL OF PATHOLOGY

Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer

(2012) Ashish Juvekar et al.   Cancer Discovery

Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents

(2012) Nicolai J. Birkbak et al.   Cancer Discovery

Double-Strand Break Repair-Independent Role for BRCA2 in Blocking Stalled Replication Fork Degradation by MRE11

(2011) Katharina Schlacher et al.   CELL

Presynaptic filament dynamics in homologous recombination and DNA repair

(2011) Jie Liu et al.   CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY

The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes

(2011) D. Blazek et al.   GENES & DEVELOPMENT

The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings

(2011) Thomas Helleday   Molecular Oncology

The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo

(2010) V. J. Weston et al.   BLOOD

PALB2/FANCN: Recombining Cancer and Fanconi Anemia

(2010) M. Tischkowitz et al.   CANCER RESEARCH

Combining ATR Suppression with Oncogenic Ras Synergistically Increases Genomic Instability, Causing Synthetic Lethality or Tumorigenesis in a Dosage-Dependent Manner

(2010) O. Gilad et al.   CANCER RESEARCH

Secondary mutations of BRCA1/2 and drug resistance

(2010) Kiranjit K. Dhillon et al.   CANCER SCIENCE

53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks

(2010) Samuel F. Bunting et al.   CELL

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers

(2010) Peter Bouwman et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination

(2010) Rémi Buisson et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Enhancement of RAD51 recombinase activity by the tumor suppressor PALB2

(2010) Eloïse Dray et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Susceptibility Pathways in Fanconi's Anemia and Breast Cancer

(2010) Alan D. D'Andrea   NEW ENGLAND JOURNAL OF MEDICINE

14-3-3 proteins, FHA domains and BRCT domains in the DNA damage response

(2009) Duaa H. Mohammad et al.   DNA REPAIR

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

(2008) Wataru Sakai et al.   NATURE

Resistance to therapy caused by intragenic deletion in BRCA2

(2008) Stacey L. Edwards et al.   NATURE

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

(2008) S. Rottenberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA